OCEAN was an open-label trial conducted in Australia, Belgium, Canada, China, Germany, and Israel. Eligible participants had ...

For patients who have undergone successful catheter ablation for atrial fibrillation, treatment with rivaroxaban does not ...

OCEAN, said Albert, provides important risk-benefit data that doctors can now use in discussions with their patients. For ...

At both 6 months and 12 months follow-up, the rivaroxaban group was found to have more of these events than the apixaban group. Credit: Getty Images. In patients with atrial fibrillation and valvular ...

If your practice is anything like mine, the question of whether rivaroxaban (Xarelto®, Bayer/Johnson & Johnson) is an effective periprocedural anticoagulant begs for an answer. Increasingly, patients ...

In patients with PAD undergoing revascularization, low-dose rivaroxaban (Xarelto; Bayer/Janssen) plus aspirin reduces the risk of venous thromboembolism (VTE) compared with aspirin alone, according to ...

The FDA has issued a complete response letter to the supplemental new drug application (NDA) for the proposed indication of rivaroxaban (Xarelto, Johnson & Johnson) in patients with acute coronary ...

Results of the highly anticipated ATLAS-ACS 2–TIMI 51 demonstrate that ACS patients receiving standard therapy, including dual antiplatelet therapy, may benefit from the addition of the factor Xa ...

An anti-stroke drug touted as more effective than older blood thinners may be riskier than doctors and patients have been led to believe. Data has shown that the drug rivaroxaban may be significantly ...

In this post, I will review these concerns and make the case that's it's too early to abandon rivaroxaban for stroke prevention in patients with AF. The new concern with ROCKET AF is an extension of ...

The Appraisal Committee considered evidence submitted by the manufacturer of rivaroxaban and a review of this submission by the Evidence Review Group (ERG). The manufacturer's submission compared ...